



CREATING VALUE WITH UNIVERSITY DISCOVERIES



INVESTOR PRESENTATION
AIM: TEK
23 Oct 2023
© 2023 Tekcapital plc
tekcapital.com

IMPORTANT NOTICE

By accepting this document, and in consideration for it being made available to such recipient, each recipient agrees to keep strictly confidential the information contained in it and any information otherwise made available by Tekcapital Plc (the "Company"), whether orally or in writing. In the case of a corporate recipient, this presentation may only be disclosed to such of its directors, officers or employees who are required to review it for the purpose of deciding whether to make an investment in the Company. This document has been provided to each recipient at their request, solely for their information, and may not be reproduced, copied, published, distributed or circulated, to any third party, in whole or in part, or published in whole or in part for any purpose, without the express prior consent of the Company. The purpose of this document is solely to provide information to persons who have expressed an interest in investigating the possibility of investing in the Company.

The information contained in this confidential document (the "Presentation") has been prepared and distributed by the Company. It has not been fully verified and is subject to material updating, completion, revision, verification and further amendment. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This Presentation does not constitute, and the Company is not making, an offer of transferable securities to the public within the meaning of sections 85B and 102B of FSMA and it is being delivered for information purposes only to a very limited number of persons and companies who are 'qualified investors' within the meaning of section 86(7) of FSMA purchasing as principal or in circumstances under section 86(2) of FSMA, as well as persons who have professional experience in matters relating to investments and who fall within the category of persons set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or are high net worth companies within the meaning set out in Article 49 of the Order or are certified sophisticated investors within the meaning set out in Article 50 of the Order or are a "professional client" or an "eligible counterparty" within the meaning of Article 4 (1) (II) and 24(2), (3) and (4), respectively, of Markets in Financial Instruments Directive (Directive 2004/39/EC) ("MiFID") as MiFID is implemented into national law of the relevant EEA state or are otherwise permitted to receive it (together, the "Relevant Persons"). This Presentation is directed only at Relevant Persons and must not be acted on or relied upon by persons who are not Relevant Persons. Any other person who receives this Presentation should not rely or act upon it. By accepting this Presentation and not immediately returning it, the recipient is deemed to represent and warrant that: (i) they are a person who falls within the above description of persons entitled to receive the Presentation; (ii) they have read, agree and will comply with the contents of this notice; and (iii) they will use the information in this document solely for evaluating your possible interest in acquiring securities of the Company.

The securities mentioned herein have not been and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any U.S. State securities laws, and may not be offered or sold in the United States of America or its territories or possessions (the "United States") unless they are registered under the Securities Act or pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. Neither this Presentation nor any copy of it may be taken or transmitted into the United States, or distributed, directly or indirectly, in the United States, or to any "US person" as defined in Regulation S under the Securities Act of 1933, including US resident corporations or other entities organised under the laws of the United States or any state thereof or non-U.S. branches or agencies of such corporations or entities. This Presentation is not being made available to persons in Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or any other jurisdiction in which it may be unlawful to do so and it should not be delivered or distributed, directly or indirectly, into or within any such jurisdictions.

The information described in this Presentation may contain certain material information that is confidential, price-sensitive and which has not been publically disclosed. By your receipt of this Presentation you recognise and accept that some or all of the information in this Presentation may be "inside information" as defined in Article 7 of the Market Abuse Regulation EU 596/2014 ("MAR"), Section 118C of the FSMA, section 56 of the Criminal Justice Act 1993 ("CJA") and the Disclosure and Transparency Rules ("DTRs") and constitutes a "market sounding" for the purpose of Article 11 of MAR. You recognise and accept that such information is being provided to you by the Company pursuant to Article 11 of MAR and DTR 2.5.7G(2)(b) and you confirm, warrant and undertake that you will not: (i) deal in securities that are price-affected securities (as defined in the CJA) in relation to the inside information, encourage another person to deal in price-affected securities or disclose the information except as permitted by the CJA or MAR or before the inside information is made public; (ii) or cancel or amend an order which has already been placed concerning a financial instrument (as defined in MAR) to which the inside information relates; (iii) deal or

attempt to deal in a qualifying investment or related investment (as defined in MAR) on the basis of the inside information; (iv) disclose the inside information to another person other than in the proper course of the exercise of your employment, profession or duties; or (v) engage in behaviour based on any inside information which might amount to market abuse or market manipulation for the purposes of MAR. Recipients should take their own legal advice on the obligation to which they will be subject and the application of MAR and in particular make their own assessment of whether they are in possession of inside information and when such information ceases to be inside information.

Prospective investors must rely on their own examination of the legal, taxation, financial and other consequences of an investment in the Company, including the merits of investing and the risks involved. Prospective investors should not treat the contents of this Presentation as advice relating to legal, taxation or investment matters and are advised to consult their own professional advisers concerning any acquisition of shares in the Company.

Certain of the information contained in this Presentation has been obtained from published sources prepared by other parties. Certain other information has been extracted from unpublished sources prepared by other parties which have been made available to the Company. The Company has not carried out an independent investigation to verify the accuracy and completeness of such third party information. No responsibility is accepted by the Company or any of its directors, officers, employees or agents for the accuracy or completeness of such information.

All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation. In addition, this Presentation contains certain "forward-looking statements", including but not limited to, the statements regarding the Company's overall objectives and strategic plans, timetables and capital expenditures. Forward-looking statements express, as at the date of this Presentation, the Company's plans, estimates, forecasts, projections, opinions, expectations or beliefs as to future events, results or performance. Forward-looking statements involve a number of risks and uncertainties, many of which are beyond the Company's control, and there can be no assurance that such statements will prove to be accurate. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its directors, officers, employees or agents in respect thereof. The Company does not undertake to update any forward-looking statement or other information that is contained in this Presentation. Neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the information contained in this Presentation or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of contract, commitment or recommendation on the part of the Company or the directors of the Company to proceed with any transaction or accept any offer and the right is reserved to terminate any discussions or negotiations with any prospective investors. The Company reserves the right without any notice or liability to the recipient of this Presentation or its advisers to: (i) change any of the procedures, timetable or requirements or terminate negotiations at any time prior to the signing of any binding agreement with investors; (ii) provide different information or access to information to different persons; (iii) agree variations to the property, rights and liabilities comprised in the Company; and (iv) negotiate at the same time with more than one person. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. This Presentation should not be considered a recommendation by the Company or any of its affiliates in relation to any prospective acquisition of shares in the Company. Please be aware that the Company's net asset value and financial results will fluctuate due to a wide variety of Company specific and macro-economic conditions.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or any of its affiliates, any of its directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted for any such information or opinions or for any errors or omissions.



TRANSFORMING UNIVERSITY DISCOVERIES INTO VALUABLE NEW PRODUCTS

1

Building portfolio companies with university technology coupled with star power management

2

Providing technology transfer services for leading universities & corporates

3

Goal: Long term growth of net assets by investing in companies that can improve people's lives.

"In addition to a growing portfolio of university IP investments, Tekcapital helps research institutions and businesses develop disruptive technologies and expand their portfolios of intellectual capital." -Julian Mitchell

Forbes

2023 H1 FINANCIAL RESULTS

OBJECTIVE

Long-term growth of Net Assets by building portfolio companies around compelling innovations that can improve people's lives.

PERFORMANCE

Net Assets US\$53.1m (31 Dec 2022: US\$57.8m)

NAV per share US\$0.32 (31 Dec 2022: US\$0.38)

Professional services revenue increased 33% to US\$0.4m (H1 2022: \$0.3m)

2023 H1 loss after tax: US\$10.1m, resulting primarily from net unrealised fair value reductions of US\$9.3m (2022 H1 profit after tax: US\$6.18m)

We ended the period with a solid balance sheet of ~ US\$ 53m in net assets, US\$2.2m in cash, US\$2.4m in receivables, modest current payables and zero debt.

TEKCAPITAL'S INVENTION DISCOVERY NETWORK



We have visibility to a large portion of the world's university-developed IP from 4,500 research institutions. This helps mitigate adverse selection and provides continuous acquisition opportunities.



PORTFOLIO COMPANIES

OWNERSHIP @ 30 JUNE 2023

Quoted



Ownership: ~11%
~ US\$6.3m



Ownership: 40%¹
~ US\$4.6m



Ownership: 91%²
~US\$18.1m



Ownership: 87%³
~US\$17.1m

¹ Tek capital owns 100% of Lucyd Ltd which owns ~ 40% of NASDAQ Quoted Innovative Eyewear Inc. its U.S. based subsidiary.

² Tekcapital owns 100% of Guident Ltd which owns ~91% of Guident Corp. its U.S. based subsidiary.

³ Tekcapital owns 87% of MicroSalt plc which owns ~92% of MicroSalt Inc, its U.S. based subsidiary

Premium Medical Devices at Value Prices

- Medical device company delivering and developing innovative and more affordable oxygen therapy products.
- 20 Oct 2023- Stonegate initiates coverage of Belluscura with an estimated 2025 midpoint valuation of \$1.09 per share <https://stonegateinc.reportablenews.com/pr/stonegate-initiates-coverage-on-belluscura-plc-aim-bell>
- Belluscura has secured circa £8m growth capital to meet the demands of recent orders and licensing royalty agreements totaling up to potentially US\$85m.
- On 16 August 2023, Belluscura announced that it had received preliminary purchase orders for its DISCOV-R™ portable oxygen concentrator. Current interest exceeding 10,000 units with a potential sales of over \$30 million.
- Simon Neicheril has been appointed as CFO, bringing extensive experience in manufacturing.
- The Hong Kong Department of Health - Medical Device Division has approved the distribution of the X-PLOR® portable oxygen concentrator.
- The Global Oxygen Concentrators is Expected to Reach \$2.92 Billion in 2025.¹

Tekcapital owns ~11% (15.1m shares) of Belluscura plc.

¹ <https://www.globenewswire.com/news-release/2021/11/03/2326359/28124/en/Global-Oxygen-Concentrators-Market-Report-2021-Market-is-Expected-to-Rreach-2-92-Billion-in-2025-at-a-CAGR-of-7-8-Forecast-to-2030.html>

X-PLO₂R Portable Oxygen Concentrator



Specifications

- Lightest:** Only 1.135kg (2.5lbs)
- Quiet:** Only 39 dB
- Reliable:** Long battery duration
- Modular:** The first FDA cleared POC with consumer replaceable filter cartridges
- Strong IP:** Through joint development with SDG, Belluscura owns or has exclusively licenced >26 patents and applications in multiple jurisdictions relating to oxygen enrichment devices and treatments.



Lucyd: the clear choice for smart eyewear

- **Goal: Upgrade your Eyewear® and develop a successful global smart eyewear business.**
- **17 Oct 2023 Innovative Eyewear, Inc. Launches the Lyte XL Smart Eyewear Collection**
- **20 June 2023 Innovative Eyewear, Inc. announced it has licensed the iconic Reebok brand for smart eyewear from Authentic Brands Group.**
- **11 April 2023 Innovative Eyewear Inc. Launches the first ChatGPT enabled smart eyewear with the Lucyd app.**
- **23 Feb 2023 Innovative Eyewear Inc. Launches Lucyd Lyte 2.0 the Next Generation Smart Eyewear on Amazon.**
- 29 Dec 2022. Innovative Eyewear, Inc. announced it has licensed the iconic outdoor brand Eddie Bauer® for smart eyewear from Authentic Brands Group.
- 3 Oct 2022. Innovative Eyewear, Inc. announced it has licensed the global lifestyle brand Nautica® for smart eyewear from Authentic Brands Group.
- Lucyd has 63 patents and applications covering its products.
- **The TAM for eyewear is ~\$140b¹. The current U.S. market which Innovative Eyewear is focusing on is \$28.3b²**

Tekcapital owns 100% of Lucyd Ltd. & ~40% of Innovative Eyewear Inc.

¹ <https://www.statista.com/statistics/300087/global-eyewear-market-value/>

² <https://www.statista.com/outlook/cmo/eyewear/united-states>



Lucyd Lyte 2.0. The first Chat GPT enabled eyewear

▼ 1.61% -189.23 11,595.90	LUCY ▲ 2.38% NasdaqListed +0.06 \$2.86	DJI ▼ 1.30% -409.09 31,247.33	S&P 500 INDEX ▼ 1.32% -52.22 3,914.63
COMCAST CMCSA ▼ 3.12% -1.15 \$36.75	PEPSICO PEP ▼ 1.49% -2.58 \$70.27	Apple AAPL ▼ 1.71% -2.75 \$155.26	amazon AMZN ▼ 0.84% -1.08 \$126.74
		Starbucks SBUX ▼ 3.13% -2.67 \$83.72	PayPal PYPL ▼ 2.06% -1.81 \$90.75
			BROADCOM AVGO ▲ 1.42% +7.00 \$489.01



guident

Software to enhance safety & efficiency of autonomous vehicles & ground-based delivery devices

- Goal: Provide managed software solutions for autonomous vehicle manufacturers and operators to enhance their safety. Guident has built a remote monitoring and control center (RMCC) for AV's in Florida.
- Oct 2023 - Guident forms partnership with Adastec a leading AV software provider and anticipates 50-100 vehicle monitoring projects in 2024.
- June 2023 - Guident has begin billing JTA for RMCC services.
- 24 Feb 2023 - Guident Ltd partners with Novelsat Ltd to develop a remote monitor and control solution for autonomous vehicles and devices using low earth orbit satellites. On 16 June 2023 Guident and Novelsat announced they were awarded funding by Space Florida to build a vehicle monitoring solution using satellite tracking.


- 14 Nov 2022 Guident selected to provide autonomous shuttle services for Boca Raton Innovation Campus (BRiC)
- 5 May 2022 Guident wins bid from Jacksonville, Florida Transportation Authority (JTA) to provide its remote monitoring and control services for municipal autonomous vehicles
- The market for last mile fully autonomous delivery vehicles is projected to reach \$90.21 billion by 2030.¹

Tekcapital owns 100% of Guident Ltd.



1- <https://www.alliedmarketresearch.com/autonomous-last-mile-delivery-market>

Boca Raton Innovation Campus & Shuttle Map



guident

Regenerative Shock Absorbers



MICROSALT®

Patented Low-sodium salt (MicroSalt®)

- **Goal:** Become the world's leading all natural, low-sodium salt supplier
- **17 Oct 2023** - MicroSalt® Files updated Schedule One form with London Stock Exchange.
- **19 Oct 2023** - MicroSalt® gains placement of its SaltMe! Low Sodium Crisps in Longs Drug Stores (division of CVS).
- **2 May 2023** – Microsalt partnered with a Fortune 500 retailer for placement of Microsalt® in several of their snacks, beginning with 800 stores in Q4 2023 and likely expanding across more than 7,000 store locations thereafter.
- **27 Feb 2023** - MicroSalt has received orders from Pete's Markets in Illinois and Busch's Market in Michigan for its new MicroSalt low sodium saltshakers.
- **6 Feb 2023** - MicroSalt announces partnership with US Salt LLC to distribute its saltshakers.
- **31 Jan 2023** - MicroSalt announced that [Giant Foods Maryland](#) has agreed to stock & sell MicroSalt's new table-top shakers in 160 stores.
- MicroSalt receives the [Sodium Reduction Technology Provider of the Year Award for 2022](#).



50% LESS SODIUM

Brings you closer to more customers

Consumers want reduced sodium & clean labels

Current market size

\$5.5 billion

Global sodium reduction market (as of 2022)

Tekcapital owns ~87% of MicroSalt plc
MicroSalt Ltd owns ~92% of Microsalt Inc, its U.S. subsidiary

MICROSALT[®]



Nutrition Facts

89 servings per container

Serving Size 1/4 tspn (1g)

Amount per serving
Calories **0**

% Daily Value*

Total Fat 0g **0%**

Saturated Fat 0g **0%**

Trans Fat 0g

Cholesterol 0mg **0%**

Sodium 230mg **10%**

Total Carbohydrate 0g **0%**

Dietary Fiber 0g **0%**

Total Sugars 0g

Includes 0g Added Sugars **0%**

Protein 0g

Vitamin D 0mcg **0%**

Calcium 0mg **0%**

Iron 0mg **0%**

Potassium 0mg **0%**

* The % Daily Value (DV) tells you how much a nutrient in a serving of food contributes to a daily diet. 2,000 calories a day is used for general advice.





SUMMARY

1

Tekcapital commercialises university innovations for its own portfolio and as a service for university clients.

2

We have built a high-value portfolio consisting of Belluscura, Lucyd, MicroSalt & Guident, all addressing \$B+ markets with exciting near-term growth prospects.

3

Tekcapital has a proven, multi-year track record of transforming university discoveries into valuable, needed products.

4

Tekcapital will provide special dividends to shareholders based on material monetisations from its portfolio.



Advisors

NOMAD & BROKER

SP Angel Corporate
Finance LLP
Prince Frederick House
35-39 Maddox Street
LONDON, W1S 2PP
+44 20 3470 0470

SOLICITORS

Bird & Bird LLP
12 New Fetter Lane
LONDON EC4A 1JP
+44 (0) 207 415 6000

AUDITORS

Macintyre Hudson LLP
2 London Wall Place
LONDON EC2Y 5AU
+44 (0) 207 429 4100

REGISTRARS

Computershare
Bridgewater Road
BRISTOL BS13 8AE
+44 (0) 870 702 0003

INVESTOR RELATIONS

Flagstaff Strategic and Investor
Communications
1 King Street, LONDON, EC2V 8AU
+44 (0) 207 129 1474

PARTIAL CURRENT CLIENT LIST



WHAT OUR CLIENTS SAY ABOUT US

“Tekcapital helps companies of all sizes find and acquire university discoveries to create market value. We have found their offering to be well received by our listed companies that have tried their service. “



Paul Dorfman
Managing Director
NYSE EURONEXT

“What you all do is disruptively high quality at a value no one else has been able to touch. “



Jeff Amerine
Adjunct Professor
University of Arkansas

“The analysis of the IP has been very useful and has provided a clear vision of the technologies.”



Daniela Fuentes
Directora
Dirección de Innovación y Transferencia Tecnológica
Vicerrectoría de Investigación, Santiago, Chile

“We could not be more pleased with their performance and value to our organization.”

Scott Gibson
Vice-Dean



WHAT OUR CLIENTS SAY ABOUT US

"We have had a great experience with the results of the studies we have requested."



Patricia Anguita,
SubGerente de Comercialización de Proyectos
de Innovación en Fundación COPEC-UC

"We would recommend Invention Evaluator reports to any organization looking to commercialize technologies."



Lisa Lorenzen, Executive Director
ISU Research Foundation

"IE has been an excellent tool to be able to check the strength and market potential of the technologies that we manage as a technology transfer company and investment fund in México. IE is professional, quick and affordable."



Eduardo Valtierra, CEO

"The Invention Evaluator tool has helped us to make decisions with a greater degree of certainty of the path that the technology should follow."



Jorge Darlas
Ejecutivo de Transferencia de Tecnología y Licenciamiento
Concepción, Chile

WHAT THE PRESS SAYS ABOUT US

“In addition to a growing portfolio of university IP investments, Tekcapital helps research institutions and businesses develop disruptive technologies and expand their portfolios of intellectual capital through leveraging their suite of powerful and convenient technology transfer services.”

-Julian Mitchell¹

Forbes

“Tekcapital released an app earlier this year that allows users to search for IP from their smartphones. This is a good way to get a feel for what is out there, identify technologies you may want, and get your creative wheels spinning.”

-Drew Hendricks²

Inc.

“An entrepreneur that wants to benefit from UIP [university intellectual property] would traditionally have to network with individual universities, making relationships with their technology transfer offices. But today entrepreneurs and international organizations facilitate a near frictionless system of access to that wealth of information.”

-Nick Hastreiter³

HUFFPOST

“Innovation is driving companies to look outside their internal R&D teams,” said Gross, who is the founder and CEO of Tekcapital, a University IP company... Capturing innovation from the crowd is now streamlined enough to become a part of any company’s survival kit.

-Andrew Medall

Entrepreneur⁴

1-<https://www.forbes.com/sites/julianmitchell/2017/08/22/this-ceo-has-built-the-largest-university-research-network-for-ip-investments/#7febe9593392>

2-<https://www.inc.com/drew-hendricks/3-ways-entrepreneurs-can-break-into-technology-tra.html>

3-https://www.huffpost.com/entry/the-future-of-corporate-innovation-3-ways-the-fortune_b_593d966de4b014ae8c69e193

4-<https://www.entrepreneur.com/article/304483#>